Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. (Q40523631)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 2004

Language	Label	Description	Also known as
English	Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.	scientific article published on November 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

José M Buesa

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Raquel Losa

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Aida Fernández

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Marta Sierra

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Angela Díaz

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Antonio López-Pousa

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Joaquín Fra

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

0 references

publication date

1 November 2004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

101

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2261-2269

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15484216%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

21 January 2018

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical pharmacokinetics of high-dose DTIC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20612

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40523631&oldid=1749495012"